Business Context and Reporting Period
This Form 8-K Current Report was filed by Revolution Medicines, Inc. on September 1, 2022. The report discloses a corporate governance event regarding the appointment of a principal officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the promotion of Jack Anders to the position of Chief Financial Officer, effective immediately on September 1, 2022. Mr. Anders previously served as Senior Vice President, Finance and Principal Financial and Accounting Officer.
Management Commentary and Risks
Management highlighted Mr. Anders' extensive background, including his tenure at Depomed, Inc., Elan Pharmaceuticals, Yahoo!, and Novellus Systems, as well as his prior experience at PricewaterhouseCoopers LLP. He holds a B.A. in Economics with an emphasis in Accounting from UCLA and is a former certified public accountant. He will continue to serve as the Company's Principal Financial and Accounting Officer. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Confirm the effective date of Jack Anders' promotion to CFO (September 1, 2022).
- Verify Mr. Anders' continued role as Principal Financial and Accounting Officer.
- Review the company's most recent 10-Q or 10-K for financial metrics not included in this 8-K.